Jasper Therapeutics, Inc., a Palo Alto, Calif.-based biotechnology company focused on hematopoietic cell transplant therapies, expanded its Series A financing with an additional investment of $14.1m.

The round was led by Roche Venture Fund with participation from other investors.

Jasper Therapeutics is a biotechnology company focused on hematopoietic cell transplant therapies.

The company’s lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplant.

This conditioning antibody is designed to enable safer and more effective curative hematopoietic cell transplants and gene therapies. | To read full story, visit https://startuparound.com/read/1578610807.444663/Jasper-Therapeutics-Raises-Additional-$14.1M-in-Series-A-Financing?ref=audio_experience